Skip to search formSkip to main contentSkip to account menu

Alimta

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2005
Highly Cited
2005
On August 19, 2004, pemetrexed for injection (Alimta); Eli Lilly and Company, Indianapolis, IN, http://www.lilly.com) received… 
Review
2004
Review
2004
  • A. Adjei
  • Clinical Cancer Research
  • 2004
  • Corpus ID: 31467685
Pemetrexed (ALIMTA, LY231514, MTA) is a novel antimetabolite that inhibits at least three enzymes involved in the folate pathway… 
Review
2004
Review
2004
The purpose of this report is to summarize information on pemetrexed (LY231514; MTA; Alimta; Eli Lilly and Company; Indianapolis… 
Highly Cited
2004
Highly Cited
2004
The underpinning conceptual model for the Lung Cancer Symptom Scale (LCSS), an instrument used to assess health‐related quality… 
Highly Cited
2003
Highly Cited
2003
BACKGROUND The purpose of this study was to evaluate ALIMTA (pemetrexed disodium, LY231514), a multi-targeted antifolate with… 
Review
2003
Review
2003
  • A. Adjei
  • Expert review of anticancer therapy
  • 2003
  • Corpus ID: 9881750
Pemetrexed (Alimta®) is a novel, multitargeted antifolate that inhibits at least three of the enzymes involved in folate… 
Highly Cited
2002
Highly Cited
2002
The purpose of this study was to identify predictive factors for severe toxicity caused by antifolate-chemotherapy using… 
Highly Cited
2002
Highly Cited
2002
BACKGROUND To evaluate the efficacy and safety of pemetrexed therapy for chemotherapy-naïve patients with surgically incurable… 
Highly Cited
2000
Highly Cited
2000
BACKGROUND To evaluate the activity of MTA plus cisplatin in chemotherapy-naive patients with non-small cell lung cancer (NSCLC…